In a study conducted in 118 European patients with hematological malignancies (90 with MM, 25 with NHL, 3 with HL), the combination of plerixafor + GCS-F was used to mobilize hematopoietic stem cells; the results showed the minimum cell yield (≥2 × 106 CD34+ cells/kg) was harvested in 98% of patients with MM and in 80% of those with lymphoma in a median of one apheresis [64]. This evidence concerns the gene CSF3 and non-Hodgkin lymphoma.